DrugPatentWatch Database Preview
Details for Biologics License Application: 125147
» See Plans and Pricing
Summary for BLA: 125147
| Tradename: | VECTIBIX |
| Applicant: | Amgen |
| Ingredient: | panitumumab |
| Patents: | 346 |
| Approval Date: | Sep 27, 2006 |
| Suppliers: see list | 1 |
Pharmacology for BLA: 125147
| Ingredient-type | Antibodies, Monoclonal |
| Drug Class | Epidermal Growth Factor Receptor Antagonist |
| Mechanism of Action | HER1 Antagonists |
US Patents for BLA: 125147
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | VentiRx Pharmaceuticals, Inc. (Seattle, WA) | 2030-04-21 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | University of Georgia Research Foundation, Inc. (Athens, GA) | 2039-02-26 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | Roche Molecular Systems, Inc. (Pleasanton, CA) | 2031-01-11 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | AMGEN, INC (Thousand Oaks, CA) | 2027-03-13 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | MEDIMMUNE, LLC (Gaithersburg, MD) | 2031-11-23 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
